{site_meta && site_meta.display_name} Logo

NewMediaWire

NewMediaWire distributes press releases on behalf of hundreds of publicly traded companies, as well as private corporations, non-profits and other public sector organizations. Founded and staffed by industry veterans, we offer a full complement of services including specialized delivery to financial sites and posting of photos and multimedia content. In addition, NewMediawire offers international and specialized services such as IR websites and industry specific distribution.

RSS Feed for NewMediaWire

Tether Supports Arcanum Capital's Fund II, Deepening Web3 Venture Capital Activities

December 26, 2024 — HAMILTON, BERMUDA - (NewMediaWire) - December 26, 2024 - Arcanum Capital ISA (“Arcanum Capital”) announced today that Tether, the issuer of the world’s largest stablecoin, has made a novel venture capital fund investment, into Arcanum Emerging Technologies Fund II (Offshore) ISA, an incorporated segregated account of DigitalArray ISAC Ltd. (the “Fund”), dedicated to nurturing the next generation of decentralized technologies.

Reconditioned pacemakers worked as well as new ones

November 17, 2024 — Research Highlights: Pacemakers reconditioned with an FDA-approved protocol worked as well as new devices in a study of nearly 300 people in seven low- and middle-income countries. The study compared the function and safety of reconditioned pacemakers to new devices at 90 days.

Email reminders improved flu shot rates in Denmark, notably among heart attack survivors

November 17, 2024 — Research Highlights: An electronic message to “nudge” patients to get a flu vaccine highlighting the cardiovascular benefits of flu shots improved vaccination rates among more than two million adults in three clinical trials in Denmark. The research observed greater improvements in vaccination, indicating that this nudge was particularly effective, among people with a history of heart attack.

Two-medication combo pill lowered blood pressure among adults in India

November 17, 2024 — Research Highlights: A study of three pills that combined two types of blood-pressure-lowering medications into one pill found that all combinations worked equally well among adults in India. Results from the TOPSPIN trial found that any two-medication combination lowered most study participants’ blood pressure to 140/90 mm Hg or less.

Spironolactone, a blood pressure medication, may help reduce risk of new heart failure

November 17, 2024 — Research Highlights: The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart attack or stroke. More research is needed to further explore the potential for spironolactone, a blood pressure medication, to prevent heart failure and its long-term impact on an individual’s heart health after a heart attack.

Patients taking edoxoban after heart valve surgery had lower risk of stroke, blood clots

November 17, 2024 — Research Highlights: Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and blood clot prevention in patients after heart valve replacement surgery as warfarin, the current standard treatment. Unlike warfarin, edoxaban does not require regular blood tests to monitor clotting activity and does not interact with food or other medications, which simplifies treatment for patients, researchers noted.

Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death

November 17, 2024 — Research Highlights: The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries involving bypass did not result in significant benefits at preventing death, stroke or organ injury compared to a placebo. Researchers noted, however, additional research is needed to determine if there are any benefits from other GLP-1 medications or from administration of exenatide for a longer period of time or at a larger dose than was tested in this study.

AI image-recognition program could read heart images faster, speed care

November 16, 2024 — Research Highlights: A new software program that uses artificial intelligence to read echocardiograms may reduce the wait times for results and lead to more timely medical care. PanEcho is the first AI system to automatically assess all key areas of heart health from echocardiograms with images from multiple views and identify which views are most relevant for each imaging task.

Giving pharmacists feedback improved care for veterans with heart failure

November 16, 2024 — Research Highlights: Pharmacists in the Veterans Health Administration System who received feedback on their patients’ heart failure medication rates, along with educational tools and targeted information, had a significant increase in the frequency at which they managed heart failure and adjusted heart failure medications in their patient populations. Providing primary care pharmacists with real-time feedback is a practical intervention that could improve heart failure and chronic disease management, the researchers noted.

Blood thinners didn t reduce cognitive decline in adults 65 and younger with AFib

November 16, 2024 — Research Highlights: In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline, stroke or transient ischemic attack (TIA) in people younger than age 65 who had atrial fibrillation (AFib) but no other stroke risk factors. AFib is the most common type of irregular heart rhythm in the U.

Ablation may be better than medication for those with dangerous heartbeat after heart attack

November 16, 2024 — Research Highlights: A new, multicenter study demonstrated that ablation treatment may be a better first option than medication for many heart attack survivors who develop abnormal electrical short circuits in their heart, which are episodes of dangerous rapid heart rhythms that can lead to fainting, heart failure or cardiac arrest. Currently, there are two main types of treatments used to prevent rapid heart rhythms: medications, which are usually used first, and if those fail, then a minimally invasive procedure called catheter ablation, in which the abnormal electrical circuits are cauterized.